#USA #Columbus #retinitis pigmentosa #Andelyn Biosciences #Celliaz

Andelyn Biosciences and Celliaz Collaborate for Gene Therapy

In a groundbreaking collaboration, Andelyn Biosciences, a prominent player in the field of cell and gene therapy, has announced a strategic partnership with Celliaz Co., Ltd., a South Korean biotechnology firm. This partnership aims to develop an adeno-associated virus (AAV)-based gene therapy, designated CLZ002, aimed at treating retinitis pigmentosa (RP), a significant cause of vision loss affecting millions worldwide.

Understanding Retinitis Pigmentosa

Retinitis pigmentosa encompasses a variety of inherited retinal diseases that can lead to progressive vision loss. With over 3 million individuals around the globe affected by RP, finding effective treatment options is essential yet remains a challenge in the medical field. Traditional therapies have struggled to address the underlying genetic mutations that contribute to this disorder. In contrast, CLZ002 represents a promising new approach: it aims to block PROX1, a protein that inhibits the regenerative capacity of Müller glial cells—critical cells in the retina.

The Partnership's Innovative Strategy

Matt Niloff, Chief Commercial Officer at Andelyn, expressed enthusiasm about the collaboration, stating, “RP represents a significant unmet need within the field of ophthalmology. Celliaz’s approach, combined with Andelyn's extensive expertise in AAV technologies, makes this partnership a compelling opportunity. We are proud to utilize our innovative Curator® Suspension Platform for this endeavor.”

This platform will facilitate comprehensive development and manufacturing services for Celliaz, positioning them to efficiently navigate the challenges of bringing CLZ002 into clinical trials.

Dr. Kyung Hwa Kang, CEO of Celliaz, emphasized the uniqueness of their gene therapy approach: “Traditional gene therapies usually target specific genetic mutations. Our therapy, however, focuses on enhancing the retina's inherent regenerative abilities by inhibiting PROX1 transfer. This broad strategy could potentially aid patients with RP caused by a diverse spectrum of genetic anomalies.”

Accelerating Gene Therapy Development

Andelyn Biosciences, equipped with over 20 years of experience and a robust FDA-approved framework for manufacturing gene therapy vectors, is uniquely prepared to support Celliaz in their mission. This collaboration underscores Andelyn's goal to transition groundbreaking therapies from developmental stages into real-world treatment solutions. By leveraging its integrated manufacturing capabilities and scientific know-how, Andelyn aims to expedite the clinical implementation of CLZ002.

Looking Ahead

As they progress towards Phase 1/2 clinical trials, both companies remain committed to addressing the pressing needs of RP patients. The collaboration signifies a potential shift in therapeutic modalities within the ophthalmic field, offering hope for meaningful advancements in regenerative medicine. With ongoing research and development efforts, Andelyn Biosciences and Celliaz are poised to revolutionize treatment options for retinal degenerative diseases and enhance the quality of life for affected individuals. If successful, CLZ002 could open avenues for similar future therapies targeting other genetic-related ocular conditions.

In conclusion, the partnership between Andelyn Biosciences and Celliaz represents not just a joint business venture, but a pivotal effort towards pioneering effective treatments in the realm of genetic therapies. Both organizations are diligently working toward a future where vision restoration becomes a reality for millions suffering from retinal disorders.